The Journal of Urology® Home Study Course 2023 Volume 209/210.

Abstract

You have accessJournal of UrologyCME1 Mar 2023The Journal of Urology® Home Study Course 2023 Volume 209/210 View All Author Informationhttps://doi.org/10.1097/JU.0000000000003137AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail AUA CME Requirements Program Description and Objectives:The Journal of Urology® Home Study Course is a comprehensive learning activity developed by a team of educators, academicians and clinicians. After completing each lesson, the participants will be able to assess their knowledge of urology, demonstrate an increased knowledge base of urology, and apply the increased knowledge to improve quality of patient care. Target Audience:The Journal of Urology® Home Study Course is designed for practicing urologic physicians, American Board of Urology (ABU) candidates and/or residents. Estimated time to complete each lesson: 2.0 hours. Program Enrollment: Enroll by visiting AUAnet.org/JUHS. Method of participation in the learning process: Two volumes of The Journal of Urology® are published annually. Each volume is comprised of 6 issues. Five clinically relevant articles are selected by the editor to be offered for CME in each issue of The Journal. For CME credit, the participant must be enrolled in the home study course for the year, read the educational material provided, pass the corresponding online posttest with 80% accuracy, submit the online evaluation and claim CME. Please go to: AUAnet.org/JU23. Each issue is designated for a maximum of 2.0 AMA PRA Category 1 Credits™. Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation: The American Urological Association designates this enduring material for a maximum of 24.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™. Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments. Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest: Peer review for valid, evidence-based content by the AUA COI Review Work Group Attestation that clinical recommendations are evidence-based and free of commercial bias Introduction of a debate format with an unbiased moderator (pointcounterpoint) Inclusion of moderated panel discussion Publication of a parallel or rebuttal article for an article that is felt to be biased Divestiture of the relationship by faculty Recusal from controlling relevant aspects of planning Selection of alternative faculty for specific topic Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to offlabel or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses. Disclosures: A complete list of disclosures can be found at AUAnet.org/JU22Disclosures. All relevant financial disclosures from the JU Editorial Board and authors have been mitigated. Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association. Release Date: Issue month, 2023. Expiration Date: Issue month, 2026. Copyright © 2023 by American Urological Association Education and Research, Inc. Email [email protected]org with any questions. CME Questions for the March 2023 Issue of The Journal of Urology® 1. Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy (vol. 209, pp. 525-531) For a patient undergoing radical cystectomy for treatment of bladder cancer, which of the following represents the increased odds of developing a venous thromboembolism within 90 days of surgery per unit of blood transfused intraoperatively? a) 4% b) 7% c) 10% d) 14% 2. Role for Conservative Management in Grade V Renal Trauma (vol. 209, pp. 565-572) A poor candidate for conservative management of a traumatic kidney injury is a patient with which of the following characteristics? a) Functional solitary kidney b) American Association for the Surgery of Trauma grade V injury c) Poor response to resuscitation d) Age <18 years 3. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach (vol. 209, pp. 540-548) When counseling patients considering active surveillance for low-risk prostate cancer, what is the expected metastases-free survival at 10 years based on real-world evidence? a) 98% to 100% b) 97% to 99% c) 94% to 96% d) 88% to 90% 4. Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer (vol. 209, pp. 549-556) A patient with nonmetastatic prostate cancer recently learned that prostate tumor cells had consistently lower level of zinc compared to normal prostate tissue and was wondering if taking zinc supplementation would help slow or inhibit prostate cancer growth and invasion. What information would you discuss with him? a) It is true many in vitro and animal studies support that treatment of malignant prostate cells with zinc can inhibit prostate cancer cell migration and invasion. b) Because prostate cancer cells are low in zinc and are dividing rapidly, taking very high doses such as 100 mg/d can improve prostate cancer survival. c) Having adequate zinc intake from a healthy and balanced diet is recommended; if not possible, taking a low-dose (1-24 mg/d) zinc supplementation might be helpful. d) A and C 5. Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study (vol. 209, pp. 515-524) A 74-year-old male is referred for high-risk upper tract urothelial cancer of the right renal pelvis. The CT scan suggests the tumor invades the renal parenchyma, but the abdominal lymph nodes are not enlarged. The patient has no comorbidities, and his kidney function is well-preserved. What treatment strategy do you recommend? a) Systemic platin-based chemotherapy b) Radical nephroureterectomy including lymph node dissection c) Radical nephroureterectomy without lymph node dissection d) Systemic immunotherapy Publication date: March 2023 Expiration date: March 2026 Answers to questions and CME credit can be obtained at AUAnet.org/JU23. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue 3March 2023Page: 647-648 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Expand All Answers to questions and CME credit can be obtained at AUAnet.org/JU23. Advertisement Advertisement PDF downloadLoading ...